Promontory Therapeutics Announces Presentation on Clinical Immune Responses to PT-112 Monotherapy at the 2025 AACR Annual Meeting

Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing immunogenic small molecule approaches in oncology, will present immuno-profiling data from two Phase 2 studies of PT-112 monotherapy at the American Association for Cancer Research (AACR) Annual Meeting, which will be held from April 25 - 30, 2025 at the McCormick Place Convention Center in Chicago, IL.

The poster will present immune activation effects observed with PT-112 monotherapy in patients with pretreated thymic epithelial tumors and late-line metastatic castration-resistant prostate cancer, including increases in activated T cells and NK cells, modulation of blood cytokines, and the emergence of novel T cell clones.

Poster Session Details

Title: Anti-Cancer Immune Effects of PT-112 Monotherapy Across Two Disease Indications
Location: Poster Section 28, McCormick Place Convention Center, Chicago, Illinois
Poster Board Number: C128
Published Abstract Number: 5819
Session: Immune Response to Therapies
Session date + time:  4/29/2025 2-5PM CDT

For more information about Promontory Therapeutics and PT-112, visit www.PromontoryTx.com.

About Promontory Therapeutics

Promontory Therapeutics Inc. is a privately held, clinical stage drug development company focused on small molecule immunotherapy in cancer. Clinical data generated across three Phase 1 studies of lead molecule PT-112 have demonstrated single-agent and combination anti-cancer activity and an attractive tolerability profile. The Company's lead Phase 2 study in late-stage metastatic castration-resistant prostate cancer patients in the United States and France is completed, with pending regulatory review meetings. The company applies a borderless collaboration model for research and development work, which has been conducted in the United States, Europe and Asia. As part of its recent expansion into France, Promontory was selected as the first international company member of the Paris-Saclay Cancer Cluster, Europe's emerging biotech hub for oncology. The company also has an active Phase 2 trial underway with the National Cancer Institute (NCI) utilizing PT-112 in thymic epithelial tumors (TETs), a rare disease with no FDA approved drug, for which PT-112 has received FDA Orphan Drug designation.

CONTACT:

Promontory Therapeutics
Email: info@promontorytx.com

SOURCE Promontory Therapeutics Inc.